ArticleACS medicinal chemistry letters2013
Discovery and in Vivo Evaluation of Potent Dual CYP11B2 (Aldosterone Synthase) and CYP11B1 Inhibitors.
Article in ACS medicinal chemistry letters, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 46 citations in OpenAlex.
- Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects.Journal of translational medicine · 2014Trial
- PPAOT predictor: ARKA-RASTR strategy-driven rodent acute oral toxicity prediction for pyrazole and pyrrolidine scaffolds-based chemicals with intelligent mechanistic interpretation.Archives of toxicology · 2026Article
- Update and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome.Endocrine reviews · 2026Review
- Osilodrostat: A Novel Potent Inhibitor of 11-Beta-Hydroxylase for the Treatment of Cushing's Syndrome.TouchREVIEWS in endocrinology · 2024Review
- Discovery of a Potent Dual Inhibitor of Aromatase and Aldosterone Synthase.ACS pharmacology & translational science · 2023Article
- Cushing disease in pediatrics: an update.Annals of pediatric endocrinology & metabolism · 2023Article
- Clinical Utility of Osilodrostat in Cushing's Disease: Review of Currently Available Literature.Drug design, development and therapy · 2023Review
- Redox partner adrenodoxin alters cytochrome P450 11B1 ligand binding and inhibition.Journal of inorganic biochemistry · 2022Article
- Catalytic atroposelective synthesis of axially chiral benzonitriles via chirality control during bond dissociation and CN group formation.Nature communications · 2022Article
- Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials.Frontiers in endocrinology · 2020Review
- Development of Highly Selective Pyrimidine-Based Aldosterone Synthase (CYP11B2) Inhibitors.ACS medicinal chemistry letters · 2019Article
- Novel (2-amino-4-arylimidazolyl)propanoic acids and pyrrolo[1,2-Beilstein journal of organic chemistry · 2019Article
- Discovery of Spirocyclic Aldosterone Synthase Inhibitors as Potential Treatments for Resistant Hypertension.ACS medicinal chemistry letters · 2017Article
- Pharmacophore Modeling andFrontiers in chemistry · 2017Article
- Discovery of Triazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus Monkeys.ACS medicinal chemistry letters · 2015Article
- Discovery of Benzimidazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus Monkeys.ACS medicinal chemistry letters · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aldosterone is a key signaling component of the renin-angiotensin-aldosterone system and as such has been shown to contribute to cardiovascular pathology such as hypertension and heart failure. Aldosterone synthase (CYP11B2) is responsible for the final three steps of aldosterone synthesis and thus is a viable therapeutic target. A series of imidazole derived inhibitors, including clinical candidate 7n, have been identified through design and structure-activity relationship studies both in vitro and in vivo. Compound 7n was also found to be a potent inhibitor of 11β-hydroxylase (CYP11B1), which is responsible for cortisol production. Inhibition of CYP11B1 is being evaluated in the clinic for potential treatment of hypercortisol diseases such as Cushing's syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.